Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.

Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T

Open source

DOI: 10.1016/j.ejca.2025.115689
Published: 2025 Sep 9
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115689,
  title = {Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.},
  author = {Michel LL and Ziegler P and Kreis P and Hartkopf AD and Wallwiener M and Häberle L and John N and Kolberg HC and Hadji P and Tesch H and Ettl J and Lüftner D and Müller V and Belleville E and Wimberger P and Enzinger HM and Huebner H and Uhrig S and Hack CC and Krabisch P and Fasching PA and Wuerstlein R and Untch M and Ditsch N and Hein A and Janni W and Taran FA and Lux MP and Wallwiener D and Brucker SY and Fehm TN and Schneeweiss A and Goossens C and Engler T},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.115689},
  url = {https://doi.org/10.1016/j.ejca.2025.115689}
}

RIS

TY  - JOUR
TI  - Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
AU  - Michel LL
AU  - Ziegler P
AU  - Kreis P
AU  - Hartkopf AD
AU  - Wallwiener M
AU  - Häberle L
AU  - John N
AU  - Kolberg HC
AU  - Hadji P
AU  - Tesch H
AU  - Ettl J
AU  - Lüftner D
AU  - Müller V
AU  - Belleville E
AU  - Wimberger P
AU  - Enzinger HM
AU  - Huebner H
AU  - Uhrig S
AU  - Hack CC
AU  - Krabisch P
AU  - Fasching PA
AU  - Wuerstlein R
AU  - Untch M
AU  - Ditsch N
AU  - Hein A
AU  - Janni W
AU  - Taran FA
AU  - Lux MP
AU  - Wallwiener D
AU  - Brucker SY
AU  - Fehm TN
AU  - Schneeweiss A
AU  - Goossens C
AU  - Engler T
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.115689
UR  - https://doi.org/10.1016/j.ejca.2025.115689
ER  -

APA

LL, M., P, Z., P, K., AD, H., M, W., L, H., N, J., HC, K., P, H., H, T., J, E., D, L., V, M., E, B., P, W., HM, E., H, H., S, U., CC, H., P, K., PA, F., R, W., M, U., N, D., A, H., W, J., FA, T., MP, L., D, W., SY, B., TN, F., A, S., C, G., & T, E. (2025). Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115689

Source records

pubmed · retrieved 2026-09-27T12:05:21.138Z